A further 16 participants withdrew during the trial, leaving a protocol correct population of 124. Figure1summarisestheflowofpatientsthroughthestudy.Only two patients (both in the placebo arm) were withdrawn owing to adverse events—onedevelopedablotchyerythematousrash;the other developed diarrhoea and vomiting, headache, fever, and worseningofasthma.Diseaseseveritywascomparableinthetwo groups at baseline (table 1).